Your browser doesn't support javascript.
COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity.
Kroemer, Marie; Spehner, Laurie; Vettoretti, Lucie; Bouard, Adeline; Eberst, Guillaume; Pili Floury, Sebastien; Capellier, Gilles; Lepiller, Quentin; Orillard, Emeline; Mansi, Laura; Clairet, Anne-Laure; Westeel, Virginie; Limat, Samuel; Dubois, Maxime; Malinowski, Léa; Bohard, Louis; Borg, Christophe; Chirouze, Catherine; Bouiller, Kevin.
  • Kroemer M; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France; Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactio
  • Spehner L; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France;
  • Vettoretti L; Anesthesia and Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France; Medical Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France.
  • Bouard A; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France.
  • Eberst G; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Chest Disease, University Hospital of Besançon, F-25000 Besançon, France.
  • Pili Floury S; Anesthesia and Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France; Research Unit EA3920, Université de Franche Comté, F-25000 Besançon, France.
  • Capellier G; Medical Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France; Research Unit EA3920, Université de Franche Comté, F-25000 Besançon, France; Australian and New Zealand Intensive Care Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Austr
  • Lepiller Q; Department of Virology, University Hospital of Besançon, F-25000 Besançon, France; Research Unit EA3181, Université de Franche Comté, F-25000 Besançon, France.
  • Orillard E; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, F-25000 Besançon, France.
  • Mansi L; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, F-25000 Besançon, France.
  • Clairet AL; Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France.
  • Westeel V; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Chest Disease, University Hospital of Besançon, F-25000 Besançon, France.
  • Limat S; Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
  • Dubois M; Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France.
  • Malinowski L; Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France.
  • Bohard L; Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France.
  • Borg C; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France;
  • Chirouze C; Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France; UMR-CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000 Besançon, France.
  • Bouiller K; Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France; UMR-CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000 Besançon, France. Electronic address: kbouiller@chu-besancon.fr.
J Infect ; 82(2): 282-327, 2021 02.
Article in English | MEDLINE | ID: covidwho-728712
ABSTRACT
Adaptive Immune responses generated by SARS-CoV-2 virus in convalescent patients according to disease severity remain poorly characterized. To this end, we designed a prospective study (NCT04365322) that included 60 COVID-19 convalescent patients (1-month post infection) in two cohorts respectively entitled mild illness and severe pneumonia. The monitoring of peripheral immune responses was performed using IFNᵧ ELISpot assay. The serology index of each patient was investigated at the same time. Patients with severe pneumonia were older and had more comorbidities than patients with mild illness. T-cell responses in term of frequency and intensity were clearly distinct between mild illness and severe pneumonia patients. Furthermore, our results demonstrated that recent history of COVID-19 did not hamper viral memory T-cell pool against common viruses (Cytomegalovirus, Epstein-Barr-virus and Flu-virus). The presence of potent adaptive immunity even in patients who underwent severe pneumonia sustain the rationale for the development of protective therapeutics against SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: J Infect Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: J Infect Year: 2021 Document Type: Article